Loading...

GRANULES Granules India Ltd Investments Divestments Announcement

Grnl

GRNL

Granules India Ltd

(GRANULES)

2026 Announcement

Conference call schedule

Regulatory compliance

US FDA inspection

US FDA Inspection

Trading Window Closure

Post-Market Surveillance

Analyst Investor Meetings

Equity issuance on preferen...

Preferential issue

Transcript Release

Conference call recording

Q3 FY26 Presentation

Financial results Q3FY26

Board meeting outcome and u...

Earnings Conference Call

Board Meeting Intimation

FDA Tentative Approval

Trading window closure

Preferential Issue

Regulation 30 Disclosure

FDA inspection outcome

Preferential issue

US FDA Establishment Report

CDP rating update

FDA Inspection Outcome

R&D Center Expansion

Equity Investment

Q2 FY26 earnings call

Earnings Call Audio

Appointment and Resignation

Investor Presentation

Equity stake acquisition

Unaudited results

Product Expansion

Investor Meet Scheduled

FDA Inspection Update

Earnings Call Scheduled

Board Meeting Notice

FDA Inspection Success

Customs Penalty

Share Allotment

Earnings Call Transcript

Earnings Call Recording

Investor Presentation

Earnings Call Rescheduled

Investor Meet Scheduled

FDA Inspection Update

Earnings Call Scheduled

Management Change

AGM Notice Published

Corporate Guarantee

FDA Inspection Update

FDA Inspection Update

Earnings Call Transcript

Management Change

Earnings Call Recording

Investor Presentation

Board Meeting Outcome

Secretarial Compliance

Earnings Call Scheduled

EcoVadis Gold Rating

Office Address Change

Management Change

Acquisition Completed

Change in Management

Subsidiary Dissolved

GST Investigation Update

Management Change

FDA Warning Letter

Acquisition by Granules

CDP Rating Update

Management Change

Q3 Earnings Call

EU GMP Certificate

Earnings Call Audio

Investor Presentation

Q3FY25 Financials

Earnings Call Scheduled

Management Change

FDA Approval Announcement

FDA Inspection Update

FDA Inspection Update

Management Change

Climate Goals Validation

Sustainability Recognition

Earnings Call Transcript

FDA Inspection Success

Investor Meeting Scheduled

Earnings Call Update

Investor Presentation

Q2 FY25 Results

Earnings Call Scheduled

FDA Approval Granted

Management Change

Mobile Cancer Screening

USFDA Inspection Update

FDA Inspection Results

FDA Approval Granted

Clarification Time

ANDA Approval for Trazodone...

Analyst/Investor Meet

Meeting Intimation

Earnings Presentation Q1 FY25

Financial Results Announcement

Newspaper Publication

Investor Meeting

Shareholder Change

Earnings Update

Presentation to Analysts/In...

Financial Results

Board Meeting Outcome

Earnings Conference Call

Tax Liability Communication

ANDA Approval for Colchicin...

Annual Secretarial Complian...

Compliance Certificate Subm...

Compliance Certificate Subm...

FDA Audit Results

Tax Liability Communication

Update on US FDA Inspection

Director Change

Management Change

Clarification on Directors ...

Management Change

Management Change

Meeting Intimation

Postal Ballot Notice Public...

Corporate Guarantee Disclosure

Appointment of Director

Appointment of Additional D...

Change in Senior Management

Earnings Conference Call

Conference Call

Earnings Presentation

Financial Results

Appointment of Directors

Earnings Conference Call

US FDA Inspection

FDA Approval - Sildenafil f...

Investor Conferences

Tax Liability Communication

Earnings Call Transcript

Analyst/Investor Meeting

Conference Call Recording U...

Disclosure of Related Party...

Financial Results Presentation

Financial Results

Preponement of Earnings Con...

Allotment of ESOS

MSCI ESG Rating Update

Analyst/Investor Meeting

Approval from Brazilian Hea...

Accreditation Certificate f...

Earnings Conference Call

Investor Meetings

Investor Meetings

Presentation to Analysts/In...

Financial Statements

Post-Market Surveillance

Publication of Meeting Notice

New Product Launches

Inspection Result

Management Changes

Completed Inspection

Regulatory Compliance

Compliance Report submission

Meeting Schedule

Conference Call Transcript

Related Party Transactions

Submission of Investor Pres...

Financial Statements

External Links:

Data:

Granules India approves preferential issue of 2.5 crore warrants convertible into equity and 51.28 lakh equity shares to promoter/non-promoter investors, expanding capital and potential dilution over 18 months.

AI Assistant

Granules India Ltd

2026

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.